TY - JOUR
T1 - Management of Antiphospholipid Syndrome in Pregnancy
AU - Petri, Michelle
AU - Qazi, Umair
N1 - Funding Information:
The Lupus Cohort was supported by NIAMS R01 #AR43737 and the Johns Hopkins University General Clinical Research Center M01-RR00052. This work was supported by the Kirkland Scholar Program.
PY - 2006/8
Y1 - 2006/8
N2 - APS pregnancy losses are one of the most common treatable causes of recurrent pregnancy loss. Clinical trials have helped in delineating the dangers of prednisone use in pregnancy, and suggest that heparin and aspirin regimens are preferred. However, the clinical trials suffer from the lack of uniform definition of antiphospholipid antibody positivity, from inclusion of women with different past pregnancy histories, and from different timing of the onset of the therapeutic modalities tested. New research on the role of complement activation in murine APS pregnancy loss may change therapeutic options in the future.
AB - APS pregnancy losses are one of the most common treatable causes of recurrent pregnancy loss. Clinical trials have helped in delineating the dangers of prednisone use in pregnancy, and suggest that heparin and aspirin regimens are preferred. However, the clinical trials suffer from the lack of uniform definition of antiphospholipid antibody positivity, from inclusion of women with different past pregnancy histories, and from different timing of the onset of the therapeutic modalities tested. New research on the role of complement activation in murine APS pregnancy loss may change therapeutic options in the future.
UR - http://www.scopus.com/inward/record.url?scp=33746630917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746630917&partnerID=8YFLogxK
U2 - 10.1016/j.rdc.2006.05.007
DO - 10.1016/j.rdc.2006.05.007
M3 - Review article
C2 - 16880086
AN - SCOPUS:33746630917
SN - 0889-857X
VL - 32
SP - 591
EP - 607
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
IS - 3
ER -